Crossmark

Can we develop real-world prognostic models using observational healthcare data? Large-scale experiment to investigate model sensitivity to database and phenotypes

Crossref DOI link: https://doi.org/10.1186/s41512-025-00191-x

Published Online: 2025-04-17

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Reps, Jenna M.

Rijnbeek, Peter R.

Ryan, Patrick B.
License Information

Text and Data Mining valid from 2025-04-17

Version of Record valid from 2025-04-17
More Information

Article History

Received: 24 July 2024

Accepted: 9 April 2025

First Online: 17 April 2025

Declarations

:

: The use of the anonymized data in this study was reviewed by the New England Institutional Review Board and was determined to be exempt from broad Institutional Review Board approval.

: Not applicable.

: JMR and PBR are employees and shareholders of Johnson & Johnson. PRR works for a research group that received/receives unconditional research grants from Yamanouchi, Pfizer-Boehringer Ingelheim, Novartis, GSK, Chiesi, Astra-Zeneca, Amgen, Janssen Research & Development.

Document is current

Any future updates will be listed below